Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding primary hypereosinophilic syndrome is largely due to its rarity, which affects fewer than 1 in 100,000 people. This extreme rarity makes it challenging to conduct systematic clinical studies and gather comprehensive data on its clinical features and treatment options. Additionally, the variability in symptoms and the overlap with other conditions complicate the characterization of HES.
To navigate your care for primary hypereosinophilic syndrome, seek out a hematologist or an immunologist with experience in eosinophilic disorders. These specialists can provide tailored management strategies. Additionally, consider participating in clinical trials to access cutting-edge treatments. You can find a directory of clinical trials at ClinicalTrials.gov. Although there are currently no specific patient organizations for HES, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information.
Currently, there are three active clinical trials investigating treatment options for primary hypereosinophilic syndrome. Notably, mepolizumab is an FDA-approved drug for this condition, while benralizumab and Dexpramipexole are designated orphan drugs in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for primary hypereosinophilic syndrome: https://clinicaltrials.gov/search?cond=primary%20hypereosinophilic%20syndrome.
Actionable guidance for navigating care for primary hypereosinophilic syndrome
To navigate your care for primary hypereosinophilic syndrome, seek out a hematologist or an immunologist with experience in eosinophilic disorders. These specialists can provide tailored management strategies. Additionally, consider participating in clinical trials to access cutting-edge treatments. You can find a directory of clinical trials at ClinicalTrials.gov. Although there are currently no specific patient organizations for HES, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding primary hypereosinophilic syndrome is largely due to its rarity, which affects fewer than 1 in 100,000 people. This extreme rarity makes it challenging to conduct systematic clinical studies and gather comprehensive data on its clinical features and treatment options. Additionally, the variability in symptoms and the overlap with other conditions complicate the characterization of HES.
To navigate your care for primary hypereosinophilic syndrome, seek out a hematologist or an immunologist with experience in eosinophilic disorders. These specialists can provide tailored management strategies. Additionally, consider participating in clinical trials to access cutting-edge treatments. You can find a directory of clinical trials at ClinicalTrials.gov. Although there are currently no specific patient organizations for HES, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information.
Currently, there are three active clinical trials investigating treatment options for primary hypereosinophilic syndrome. Notably, mepolizumab is an FDA-approved drug for this condition, while benralizumab and Dexpramipexole are designated orphan drugs in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for primary hypereosinophilic syndrome: https://clinicaltrials.gov/search?cond=primary%20hypereosinophilic%20syndrome.
Actionable guidance for navigating care for primary hypereosinophilic syndrome
To navigate your care for primary hypereosinophilic syndrome, seek out a hematologist or an immunologist with experience in eosinophilic disorders. These specialists can provide tailored management strategies. Additionally, consider participating in clinical trials to access cutting-edge treatments. You can find a directory of clinical trials at ClinicalTrials.gov. Although there are currently no specific patient organizations for HES, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding primary hypereosinophilic syndrome is largely due to its rarity, which affects fewer than 1 in 100,000 people. This extreme rarity makes it challenging to conduct systematic clinical studies and gather comprehensive data on its clinical features and treatment options. Additionally, the variability in symptoms and the overlap with other conditions complicate the characterization of HES.
To navigate your care for primary hypereosinophilic syndrome, seek out a hematologist or an immunologist with experience in eosinophilic disorders. These specialists can provide tailored management strategies. Additionally, consider participating in clinical trials to access cutting-edge treatments. You can find a directory of clinical trials at ClinicalTrials.gov. Although there are currently no specific patient organizations for HES, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information.
Currently, there are three active clinical trials investigating treatment options for primary hypereosinophilic syndrome. Notably, mepolizumab is an FDA-approved drug for this condition, while benralizumab and Dexpramipexole are designated orphan drugs in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for primary hypereosinophilic syndrome: https://clinicaltrials.gov/search?cond=primary%20hypereosinophilic%20syndrome.
Actionable guidance for navigating care for primary hypereosinophilic syndrome
To navigate your care for primary hypereosinophilic syndrome, seek out a hematologist or an immunologist with experience in eosinophilic disorders. These specialists can provide tailored management strategies. Additionally, consider participating in clinical trials to access cutting-edge treatments. You can find a directory of clinical trials at ClinicalTrials.gov. Although there are currently no specific patient organizations for HES, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.